.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Baxter
Colorcon
Cipla
Julphar
McKesson
Accenture
Teva
US Department of Justice
AstraZeneca

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020768

« Back to Dashboard
NDA 020768 describes ZOMIG, which is a drug marketed by Astrazeneca and IPR and is included in three NDAs. It is available from four suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ZOMIG profile page.

The generic ingredient in ZOMIG is zolmitriptan. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

Summary for NDA: 020768

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020768

Suppliers and Packaging for NDA: 020768

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOMIG
zolmitriptan
TABLET;ORAL 020768 NDA Global Pharmaceuticals, Division of Impax Laboratories Inc. 0115-0671 0115-0671-51 1 BLISTER PACK in 1 CARTON (0115-0671-51) > 6 TABLET in 1 BLISTER PACK
ZOMIG
zolmitriptan
TABLET;ORAL 020768 NDA Global Pharmaceuticals, Division of Impax Laboratories Inc. 0115-0672 0115-0672-50 1 BLISTER PACK in 1 CARTON (0115-0672-50) > 3 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:Nov 25, 1997TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Nov 25, 1997TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 020768

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-001Nov 25, 1997► Subscribe► Subscribe
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-002Nov 25, 1997► Subscribe► Subscribe
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-002Nov 25, 1997► Subscribe► Subscribe
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-001Nov 25, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Queensland Health
Deloitte
Novartis
Medtronic
Dow
Boehringer Ingelheim
Colorcon
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot